Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Telesat Corporation has secured a $2.3 billion contract with Canada's Defence Investment Agency to deliver secure Mil-Ka satellite connectivity to the Canadian Armed Forces across the Arctic. This 15-year agreement expands Telesat Lightspeed constellation by 69 satellites to 225 total, increasing capacity by 44% and positioning Telesat for accelera…
Abeona Therapeutics announced that CMS has granted New Technology Add-On Payment (NTAP) status for its gene therapy ZEVASKYN, intended to treat wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). NTAP status offers supplemental reimbursement above standard hospital payments, recognizing the therapy's clinical benefits and imp…
3D Systems disclosed that CEO Dr. Jeffrey Graves will retire later this year, with a successor to be appointed through an ongoing search process. Dr. Graves will continue as CEO until then and serve as a consultant afterward to ensure a smooth transition. The company highlights the strategic progress made under his leadership, including a focus on …
Creative Realities, Inc., a NASDAQ-listed provider of digital signage and media solutions, will report its financial results for Q2 2026 on August 13, 2026, before market open, followed by a conference call hosted by senior management. The company designs and deploys digital signage experiences and offers SaaS across various sectors including retai…
Harmony Biosciences announced a 30% year-over-year increase in Q2 2026 net revenue for WAKIX, reaching $261.3 million, driven by strong demand and commercial execution. Patient numbers grew by 450 to 8,950. The company reaffirmed its 2026 WAKIX net revenue guidance between $1.0 billion and $1.04 billion. Phase 1 data for BP-205, a potential best-in…
Zevra Therapeutics, a commercial-stage biotech company specializing in rare disease therapeutics, announced its executive leadership will present at the Canaccord Genuity 46th Annual Growth Conference to discuss corporate strategy and upcoming milestones. The company emphasizes its ongoing commercialization of therapies for Niemann-Pick disease typ…
Palvella Therapeutics reported second quarter 2026 financial results and a corporate update highlighting the submission of the first module of its rolling NDA for QTORIN™ rapamycin targeting microcystic lymphatic malformations, planned commercial launch in H1 2027, and upcoming clinical trial initiations for other QTORIN™ drug candidates. The compa…
Dyadic International announced a new strategic development and commercial license agreement with a European biotech firm to expand its portfolio of precision-fermented non-animal dairy proteins. This move enhances Dyadic's food and nutrition pipeline, building on existing collaborations and utilizing its proprietary Dapibus™ fermentation platform f…
Microchip Technology, in collaboration with Micron Technology, showcased an advanced PCIe Gen 6 storage architecture integrating Microchip's Switchtec Gen 6 PCIe switches with Micron's 9650 NVMe SSDs. This demonstration highlights enhanced data throughput, reduced latency, and scalable connectivity designed to meet the demanding requirements of AI,…
Constellation Energy (CEG) is the largest U.S. operator of nuclear capacity and is trading well below its 52‑week peak after a recent pullback. With government support for nuclear, hyperscaler contracts, attractive technical momentum, and a reasonable valuation (EV/EBITDA ~14.9), I recommend a long position sized for medium risk with a clear entry,…
Xometry, Inc. (NASDAQ: XMTR) announced record second quarter 2026 results highlighted by 41% year-over-year revenue growth to $229 million, with marketplace revenue increasing 45%. Gross profit rose 34% to $87.2 million, and Adjusted EBITDA improved significantly to $14.1 million, driven by the company's AI-native marketplace expansion, network gro…
Superior Group of Companies, Inc. announced its second quarter 2026 financial results, reporting net sales of $147.8 million, a slight increase from the prior year. Despite a non-cash tradename impairment charge impacting net income to $1.2 million, adjusted net income rose to $3.2 million with adjusted EPS doubling year-over-year. The company conf…
SK hynix rallied in pre-market trading after detailing a new High Bandwidth Flash (HBF) standard with SanDisk at FMS 2026 and disclosing its tenth-generation V10 375-layer 4D NAND. The announcement, which positions HBF between HBM and SSDs for AI inference workloads, plus upbeat analyst initiations and a firmer macro backdrop, drove a notable pre-o…
IREN Limited has completed the acquisition of Mirantis, a cloud software and services provider, enhancing IREN's AI workload orchestration, monitoring, and customer support capabilities. This acquisition strengthens IREN’s vertically integrated AI Cloud platform by combining their owned data centers and compute infrastructure with Mirantis' robust …
Invivyd, Inc. announced the grant of stock options totaling 277,500 shares to ten newly hired non-executive employees as inducements under Nasdaq Listing Rule 5635(c)(4). These options have an exercise price of $0.535, matching the stock's closing price on July 31, 2026, with a four-year vesting period and a 10-year term. This move aims to attract …
Rhythm Pharmaceuticals announced its Q2 2026 financial results, highlighting a robust U.S. launch of IMCIVREE for acquired hypothalamic obesity, with over 400 patient starts since FDA approval. Net product revenue reached $71.3 million globally, a 19% sequential increase, driven by strong U.S. sales and growing patient reimbursement. The company al…
Larimar Therapeutics reported encouraging long-term safety and efficacy data for nomlabofusp in an open-label study for Friedreich's ataxia, submitted the first module of a rolling Biologics License Application with the FDA seeking accelerated approval, and plans to start a global Phase 3 confirmatory study in Q3 2026. The company has a strong cash…
Descartes Systems Group will announce its second quarter fiscal 2027 financial results after market close on September 10, 2026. The company's executive management will host a conference call and webcast to discuss the results, providing investors and stakeholders with insight into its performance in the logistics technology sector.
RYTHM, Inc. reported robust financial results for Q2 2026, with revenue from continuing operations reaching $23 million, up 73% quarter-over-quarter. The company achieved net income of $1.2 million and an adjusted EBITDA of $6.4 million, marking a significant turnaround from breakeven in the prior quarter. Growth in THC beverage shipments and new s…
Aclarion, Inc. announced that its Nociscan platform for identifying the source of chronic low back pain is now available at Goodman Campbell Brain & Spine at Ascension St. Vincent, the first site in Indiana to offer this technology. This expansion marks growth in Aclarion's provider network and aligns the company with a nationally recognized neuros…
iBio, a clinical-stage biotechnology company focused on long-acting antibody therapeutics for obesity and cardiometabolic diseases, has appointed Dr. Molly Carr as Chief Medical Officer. Dr. Carr brings over 30 years of experience in endocrinology and metabolic disease, having held senior roles at major biopharmaceutical companies. Her leadership i…
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company focusing on novel FASN inhibitors targeting metabolic and fibrotic pathways, announced management's participation in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026.
CAMP4 Therapeutics completed the second closing of a $100 million private placement, raising approximately $50.1 million to fund clinical development of CMP-002, a lead antisense oligonucleotide targeting SYNGAP1-related disorder, and other early-stage programs. The company aims to initiate a Phase 1/2 trial in Australia, advancing its pipeline of …
Shoals Technologies Group, Inc., a leader in electrical infrastructure solutions for the energy transition, reported strong Q2 2026 financial results, with revenue increasing 47.4% to $163.4 million and a record backlog and awarded orders of $801.4 million. Although gross margin declined primarily due to operational inefficiencies from transitionin…
X-Energy's subsidiary TRISO-X has acquired an additional 70 acres adjacent to its Oak Ridge, Tennessee nuclear fuel campus, expanding its total footprint to approximately 180 acres. This expansion supports construction and long-term growth plans for advanced nuclear fuel fabrication facilities and research capabilities, reinforcing the region’s lea…
